Knowledge Library
NK Cell Humanized Tumor Models
NK cells are effector innate lymphoid cells (ILCs) that do not require antigen-specific priming. NK cells are not only killer cells that help to suppress tumors, but also are involved in the generation and maintenance of adaptive immune responses. The process of antibody-dependent cell-mediated cytotoxicity (ADCC) makes use of innate immune cells which provide antitumor …Read More >
Orthotopic and Metastasis Tumor Models in Rats
Rat tumor models are a better mimic of human pathology compared to mice. The tumor stroma component of rats is about 1.5 to 2-fold higher relative to mice. Rats are considered an ideal model for preclinical efficacy studies, as they are physiologically, metabolically, and genetically more similar to humans. To support drug discovery teams, WuXi …Read More >
Armoring CAR-T Therapy with PD-1 Blockade
The efficacy of CAR-T therapy is substantially influenced by the tumor microenvironment. This is particularly evident when PD-L1 is activated through CAR-T, leading to the inhibition of CAR-T cell activity via the PD-1 pathway. At AACR 2024, WuXi AppTec presented a poster describing an engineered CAR-T therapy that targets mesothelin and concurrently expresses a membrane-bound …Read More >
OncoWuXi Express: PSMA Overexpressing PC3 Tumor Model
Introduction: OncoWuXi Express will continue to keep you informed about updates to our on-line tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we would like to share with you the newly established PSMA-overexpressing PC3 prostate cancer model. https://onco.wuxiapptec.com Globally, prostate cancer stands not only …Read More >
AACR 2024 Posters: Sneak Peek
AACR 2024 Sneak Peek | Your All-In-One Guide to WuXi Biology’s Latest Advances in Cancer Research The American Association for Cancer Research (AACR) Annual Meeting 2024, one of the largest global cancer research conferences, will take place from April 5 to 10 at the San Diego Convention Center. This year, WuXi Biology has been selected …Read More >
T-DXd Resistant Tumor Models with ABCG2
Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies. However, primary and secondary resistance is frequently observed, and development of next generation ADCs necessitates the establishment of resistant tumor models. One mechanism of resistance involves efflux of the ADC payload by the transporter …Read More >
OncoWuXi Express: Adenovirus Vaccine AD5-HPV Inhibits Tumor Growth by Stimulating Immunity
OncoWuXi Express will continue to keep you informed about updates to our on-line tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we share with you our experience in the establishment and antitumor efficacy evaluation of adenovirus vaccine AD5-HPV. https://onco.wuxiapptec.com Introduction: Adenoviruses (Ad) are non-enveloped …Read More >
Establishment of EGFR TKI-Resistant Tumor Models
Despite improvement in clinical outcomes observed with the use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs), long-term prognosis remains unfavorable due to the development of either intrinsic or acquired resistance. Understanding the mechanisms underlying this resistance is vital for designing strategies to address this challenge, and one approach involves the establishment of …Read More >
iMN041: Prodrug with a Unique Antitumor Immune Response
WuXi AppTec scientists contributed to a research article in the journal Translational Medicine Communications which characterized the antitumor immune responses generated by iMN041, a prodrug of a DNA methyl transferase/ribonucleotide reductase inhibitor. This study also assessed the efficacy of iMN041 in mouse xenografts of human clear cell renal cell cancer, pancreatic cancer, and triple negative …Read More >